Pioneering
the Future of Personalized Cancer Immunotherapy
Innovative Technology Platforms
PyroCells Personalized Cancer Vaccine Platform
Pyrojas is revolutionizing personalized cancer immunotherapy with its PyroCells platform, a rapid-response, autologous cancer vaccine technology. PyroCells are designed to address the complex heterogeneity of tumors and neutralize immunosuppressive environments, which are common obstacles in current cancer treatments.
-
Antigen-Agnostic Approach: PyroCells target the full repertoire of tumor antigens, promoting a diversified immune response that combats cancer escape mechanisms.
-
Rapid Manufacturing: A breakthrough automated system allows point-of-care production of personalized vaccines within 24 hours at the site of surgery, ensuring swift, patient-specific therapies.
-
Validated Preclinical Success: Preclinical trials have demonstrated 100% tumor protection, positioning PyroCells as a potentially transformative solution in the fight against cancer.
PyroTIMER T Cell Enhancement Platform
The PyroTIMER platform is designed to supercharge the efficacy of CAR-T and TCR-T cell therapies by overcoming the immunosuppressive tumor immune microenvironment. PyroTIMER significantly enhances T cell persistence, cytotoxicity, and delays exhaustion, allowing these therapies to be more effective in both solid tumors and refractory cancers.
-
Modular Technology: PyroTIMER molecules are adaptable, allowing for customized applications across different tumor types and immunotherapy platforms.
-
Universal Application: Validated with FDA-approved CAR-T therapies, PyroTIMER can be integrated with existing CAR/TCR technologies globally to enhance clinical outcomes.
-
Licensing Opportunities: This platform is licenseable by CAR/TCR-T cell therapy companies worldwide, enabling broad industry adoption of this powerful enhancement platform.
Join us in our mission to achieve Pyrojas, pure immunity, from human cancers
Connect
PyrOjas Corporation
180 Varick St. Floor 6
NYC, NY, 10014
Copyright © 2024 | All rights reserved.